本港新增1,873宗新冠確診 輸入個案佔154宗 政府未收到第二代疫苗註冊申請
本港新增1,719宗新冠肺炎本地確診,另有154宗輸入個案,總計1,873宗,沒有新增死亡個案。新增本地感染中有609宗為核酸檢測陽性,另外1,110宗來自快速檢測呈報再經核實後確診。新增個案中有464宗由學校呈報,涉335間學校,其中7間學校個別班級出現傳播。
另外,再有三間安老院舍出現確診個案,涉及西貢通善壇安老院、黃大仙紫雲間沁怡護養院及元朗松齡雅苑。
莫德納(Moderna)(MRNA.US)全球資深副總裁Patrick Bergstedt接受《南華早報》訪問稱,與港府就批准疫苗的商討進入成熟階段,但當局仍未開綠燈。衛生防護中心傳染病處首席醫生歐家榮在記者會上表示,政府有既定機制包括按599K章及專家意見等處理疫苗申請,目前政府未有收到第二代新冠疫苗的註冊或認可申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.